Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer.
- Author:
Qi-Sen GUO
1
;
Yan-Xia LIU
;
Jin-Ming YU
;
Jia-Lin WANG
;
Wei-Xia ZHONG
;
Xiu-Ju LIU
Author Information
- Publication Type:Journal Article
- MeSH: Carcinoma, Small Cell; enzymology; pathology; DNA Topoisomerases, Type I; metabolism; Female; Humans; Immunohistochemistry; methods; Lung Neoplasms; enzymology; pathology; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging
- From: Chinese Journal of Oncology 2007;29(2):124-126
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the expression and its significance of DNA topoisomerase I (Topo I) in small cell lung cancer (SCLC).
METHODSTopo I expression was detected by immunohistochemical S-P technique on 50 cases of SCLC and 12 cases of normal lung tissues.
RESULTSThe total positive rate of Topo I in normal lung tissue was 25.0% (3/12) and 78.0% (39/50) in SCLC. The expression of Topo I does not correlate with age, gender, smoking, tumor size and tumor site (P > 0.05), but significantly correlated with lymph node metastasis and clinical stage (P <0.05).
CONCLUSIONHigh Topo I expression is a rationale indication of Topo I inhibitor treatment of malignancies. It should be possible to predict anti-tumor drug sensitivity by assessment of Topo I expression and help to improve the therapeutic efficacy for cancer patients.
